GSK plc (NYSE:GSK) Shares Purchased by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. increased its position in shares of GSK plc (NYSE:GSK) by 51.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,414 shares of the pharmaceutical company’s stock after purchasing an additional 480 shares during the period. SRS Capital Advisors Inc.’s holdings in GSK were worth $48,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of GSK. Sunbelt Securities Inc. lifted its position in GSK by 73.8% in the third quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after acquiring an additional 302 shares during the last quarter. Indiana Trust & Investment Management Co lifted its position in GSK by 200.0% in the fourth quarter. Indiana Trust & Investment Management Co now owns 750 shares of the pharmaceutical company’s stock valued at $25,000 after acquiring an additional 500 shares during the last quarter. Crews Bank & Trust purchased a new stake in GSK in the fourth quarter valued at $26,000. ST Germain D J Co. Inc. lifted its position in GSK by 195.5% in the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 522 shares during the last quarter. Finally, Sierra Ocean LLC purchased a new stake in GSK in the fourth quarter valued at $32,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

GSK has been the subject of a number of research reports. Morgan Stanley initiated coverage on shares of GSK in a research report on Wednesday, February 12th. They issued an “equal weight” rating for the company. Jefferies Financial Group cut shares of GSK from a “buy” rating to a “hold” rating and reduced their target price for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Finally, StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Seven analysts have rated the stock with a hold rating and four have given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $43.25.

GSK Trading Up 2.0 %

NYSE GSK opened at $40.08 on Friday. The stock has a market capitalization of $83.07 billion, a P/E ratio of 25.21, a P/E/G ratio of 1.12 and a beta of 0.58. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The firm has a 50-day moving average price of $35.47 and a 200 day moving average price of $37.20. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Equities research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be issued a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a yield of 3.92%. The ex-dividend date of this dividend is Friday, February 21st. GSK’s dividend payout ratio is currently 98.74%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.